Salarius Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
SLRX Nasdaq 8731 https://salariuspharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Salarius Pharmaceuticals Inc

SLRX Pursues Important Goal - Apr 2nd, 2024 12:23 pm
Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - Mar 22nd, 2024 8:05 pm
Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses - Feb 22nd, 2024 1:00 pm
Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders - Jan 16th, 2024 1:00 pm
Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment - Jan 3rd, 2024 1:30 pm
SLRX Continues Work as it Seeks Alternatives - Nov 10th, 2023 11:21 am
Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program - Nov 7th, 2023 1:30 pm
Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update - Aug 10th, 2023 8:05 pm
SLRX Pursuing Strategic Alternatives - Aug 9th, 2023 11:39 am
Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources - Aug 8th, 2023 8:05 pm
SLRX Continues Cancer Fight with Phase I Trial Approval - Jul 11th, 2023 1:00 pm
Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients - Jul 11th, 2023 12:30 pm
Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress - Jun 12th, 2023 12:00 pm
Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - May 16th, 2023 8:05 pm
Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules - May 12th, 2023 12:00 pm
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update - May 11th, 2023 12:00 pm
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma - May 9th, 2023 12:00 pm
SLRX: Fighting Cancer Through Two Paths - May 9th, 2023 11:34 am
Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164 - May 1st, 2023 12:30 pm
Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting - Apr 20th, 2023 12:30 pm